Octagon Capital Advisors LP Has $30.57 Million Holdings in BioAge Labs, Inc. $BIOA

Octagon Capital Advisors LP boosted its holdings in BioAge Labs, Inc. (NASDAQ:BIOA) by 9.4% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 1,748,000 shares of the company’s stock after acquiring an additional 150,000 shares during the quarter. BioAge Labs accounts for approximately 3.4% of Octagon Capital Advisors LP’s portfolio, making the stock its 10th largest position. Octagon Capital Advisors LP’s holdings in BioAge Labs were worth $30,573,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Renaissance Technologies LLC grew its holdings in BioAge Labs by 653.2% during the 1st quarter. Renaissance Technologies LLC now owns 138,588 shares of the company’s stock worth $2,424,000 after acquiring an additional 120,188 shares during the period. Arrowstreet Capital Limited Partnership acquired a new position in shares of BioAge Labs in the 1st quarter valued at $1,537,000. Bank of Nova Scotia acquired a new position in shares of BioAge Labs in the 1st quarter valued at $180,000. Sei Investments Co. bought a new position in shares of BioAge Labs in the 1st quarter worth $1,091,000. Finally, Walleye Capital LLC grew its stake in shares of BioAge Labs by 12.5% during the first quarter. Walleye Capital LLC now owns 151,674 shares of the company’s stock worth $2,653,000 after purchasing an additional 16,879 shares during the period.

BioAge Labs Price Performance

Shares of BIOA stock opened at $21.77 on Monday. BioAge Labs, Inc. has a 12-month low of $4.11 and a 12-month high of $25.95. The firm has a fifty day moving average of $20.26 and a 200-day moving average of $19.37. The firm has a market capitalization of $967.74 million, a price-to-earnings ratio of -9.07 and a beta of 0.61.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.19. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%.The firm had revenue of $2.77 million for the quarter. Research analysts expect that BioAge Labs, Inc. will post -2.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Wall Street Zen lowered BioAge Labs from a “hold” rating to a “sell” rating in a research note on Sunday, May 17th. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, July 21st. BTIG Research initiated coverage on BioAge Labs in a research note on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price target for the company. Finally, Roth Capital began coverage on shares of BioAge Labs in a research report on Wednesday, May 27th. They issued a “buy” rating and a $36.00 price target on the stock. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, BioAge Labs has an average rating of “Moderate Buy” and a consensus price target of $43.50.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.